On the afternoon of March 25, Yin Li, Secretary of the Municipal Party Committee of Beijing, met with Novartis Global CEO Wansheim, Pfizer Chairman and CEO Eberle, and Danaher Global President and CEO Bjørnen.

Yin Li introduced the economic and social development of Beijing and the health condition of its residents. He said that the Beijing Municipal Government attaches great importance to residents' health, vigorously develops health care, gives full play to the advantages of rich scientific and technological talent resources, and continuously improves the level of medical services for the people in the city. Beijing's pharmaceutical and health industry has a good foundation and a perfect system. In recent years, it has laid out its biopharmaceutical industry in key areas such as cellular genes, nucleic acid drugs, new antibodies, etc., and has formed international leading source innovative varieties in the fields of antibody drugs and immunotherapy drugs. Beijing's science and technology innovation is resource-intensive and dynamic, with the intensity of R&D investment of the whole society remaining above 6%, and the rapid development of digital healthcare. It also enjoys a wealth of supportive policies in various aspects, and enjoys the advantages of the "two zones" and other superimposed open policies, and is further strengthening the policy support for the whole chain of R&D, production, and application of innovative medicines. Intellectual property protection system is perfect, with a special intellectual property court, the establishment of pharmaceutical patent linkage protection, intellectual property insurance and other systems, and continue to enhance the business environment of marketization, rule of law, facilitation and internationalization.

Yin Li said that in recent years, Beijing has made it a priority to develop the pharmaceutical and healthcare industry, especially innovative drugs, and is willing to deepen cooperation with domestic and foreign pharmaceutical enterprises to share opportunities and develop together. We hope Novartis will actively promote the expansion of its production in Beijing, increase the layout of new production lines, and promote the production of more innovative drugs in Beijing; actively enhance the capacity of R&D and innovation in Beijing, and strengthen the exchanges and cooperation with local scientific research institutes and medical institutions; and actively deepen and expand the cooperation in digital healthcare, and provide more efficient and convenient pharmaceutical services. We hope that Pfizer will strengthen R&D and clinical trial cooperation with relevant organizations in Beijing; actively introduce more innovative products to share the advantages of China's mega-market; play the role of industry leader and deepen cooperation with pharmaceutical start-ups in Beijing; and play its own technological advantages to jointly address public health challenges. We hope that Danaher Group will accelerate the operation of the Science and Innovation Center and the northern headquarters, make good use of Beijing's advantages in science and technology talents and its ability to allocate resources within the Beijing-Tianjin-Hebei region, improve the local R&D and production capacity of scientific instruments and equipment, collaborate with local enterprises to explore the international market, and further enhance the digitalization of products and services.

Wansheim said that the Chinese market is very important to Novartis, we will continue to expand the production capacity of Changping plant, introduce more innovative drugs, strengthen R&D cooperation with relevant organizations in Beijing, and continuously improve the level of digital healthcare, so as to make a greater contribution to the development of healthcare in Beijing. Pfizer is willing to further deepen and expand cooperation with Beijing in the areas of innovative R&D and addressing public health challenges," Mr. Eberle said, noting that China's pharmaceutical and healthcare industry has a huge market scale, and that Beijing's strong innovation capability and first-class business environment provide broad opportunities for pharmaceutical companies. Bearing highly appreciated Beijing's first-class innovation ecosystem, and said that Danaher Group will continue to enhance the localized R&D and production capacity of its products, increase the layout in Beijing and the surrounding areas, and explore more innovative areas of cooperation with Beijing's science and innovation enterprises and related R&D institutions.

https://mp.weixin.qq.com/s?__biz=MjM5MjYxMzUxOA==&mid=2652031107&idx=1&sn=e3e0b41256b890a2644398fe5ccf85c6&chksm=bd45fd628a327474c74875cafd89d8b9b4d26ce6a476ab68f7f2fb23e5cd2da9a2f276416b80&mpshare=1&scene=1&srcid=0328NLL13IqZhiyeVbyfLntO&sharer_shareinfo=36016694c15fad17e228fda2b72333b6&sharer_shareinfo_first=36016694c15fad17e228fda2b72333b6#rd